Lipitor Lawsuit News: Thousands of Plaintiffs to Have Lipitor Diabetes Claims Transferred to Federal Litigation, Bernstein Liebhard LLP Reports

The Firm is evaluating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Free Case Review
Our Firm hears from Lipitor patients on a regular basis who allegedly developed diabetes from this medication. We are not surprised that the number of filings in both state and federal courts has grown.

New York, NY (PRWEB) June 16, 2014

Lipitor lawsuits (http://www.thelipitorlawsuit.com/) that allege the cholesterol-lowering statin caused patients to develop Type 2 diabetes continue to mount in the federal multidistrict litigation now underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to a Status Report filed with the Court on June 6, 2014, 134 Lipitor diabetes claims that involve more than 3,000 plaintiffs are set to be transferred from the federal courts where they were filed to the multidistrict litigation. The Status Report also notes that some 300 plaintiff have filed Lipitor lawsuits in various state courts, including West Virginia, Missouri, and New York. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

“Our Firm hears from Lipitor patients on a regular basis who allegedly developed diabetes from this medication. We are not surprised that the number of filings in both state and federal courts has grown,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by this medication.

Lipitor Diabetes Allegations

According to court records, the Lipitor diabetes litigation began to grow in February 2012, after the U.S. Food & Drug Administration (FDA) mandated that the manufacturers of statin medications, including Lipitor, update their labels with information regarding their possible association with Type 2 diabetes. The FDA acted after a study published in in JAMA: Internal Medicine indicated that women using this class of medications may face an increased risk for developing the disease.*

Court documents indicate that more than 800 Lipitor lawsuits have been filed in the federal multidistrict litigation on behalf of patients who claim to have developed diabetes due to the statin. Plaintiffs who have filed cases in the proceeding allege that Pfizer, Inc. was aware of the link between Lipitor and diabetes before modifying the drug’s label in February 2012, but concealed this information in order to protect the drug’s market share. The complaints also maintain that diabetes information added to the Lipitor label in 2012 remains inadequate.

Alleged victims of Lipitor and diabetes may be entitled to compensation from Pfizer, Inc. for their injury-related damages. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.

*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993? As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thelipitorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author